MedinCell Gets ISS ESG Prime Rating for Strong CSR

Published on:
by KnowESG
Image courtesy of

Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.

The rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector.

ISS, one of the world’s leading rating agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.

MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders.

The first product based on Medincell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipeline of other products follows.

For more investor-related news

Source: MedinCell


Investors Headlines

AIDA Cruises Wins ESG Shipping Award

AIDA Cruises Wins ESG Shipping Award

Bath & Body Works Publishes 2023 ESG Report

Bath & Body Works Publishes 2023 ESG Report

Li-Cycle Releases 2023 Sustainability Report

NGFS' Reports Guide Central Banks to Invest Sustainably

REC Group Earns EcoVadis Silver Medal for Sustainability

Climate-Focused Fintech Ekko Raises $2.5 Million

Cooper Standard Publishes 2023 ESG Report

Woodspin Gets Certified for Sustainable Sourcing

HH Global Gets EcoVadis Gold Sustainability Rating

SoCalGas Publishes 2023 Corporate Sustainability Report